| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 4 | 2021 | 867 | 0.740 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2021 | 1 | 0.690 |
Why?
|
| Cell Cycle Proteins | 4 | 2020 | 187 | 0.430 |
Why?
|
| Membrane Proteins | 5 | 2019 | 485 | 0.410 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2025 | 44 | 0.410 |
Why?
|
| Neoplasm Proteins | 4 | 2019 | 123 | 0.400 |
Why?
|
| Prostatic Neoplasms | 4 | 2019 | 302 | 0.360 |
Why?
|
| Humans | 41 | 2025 | 28870 | 0.350 |
Why?
|
| Amyloid beta-Peptides | 3 | 2020 | 49 | 0.350 |
Why?
|
| Bone Marrow | 2 | 2025 | 83 | 0.340 |
Why?
|
| Alzheimer Disease | 4 | 2020 | 225 | 0.320 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 29 | 0.310 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 122 | 0.310 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 686 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 3 | 2018 | 548 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 137 | 0.260 |
Why?
|
| Blood Platelets | 4 | 1993 | 206 | 0.250 |
Why?
|
| Antigens, CD | 4 | 1995 | 140 | 0.240 |
Why?
|
| CD36 Antigens | 3 | 2001 | 8 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1995 | 59 | 0.220 |
Why?
|
| Spheroids, Cellular | 1 | 2024 | 53 | 0.210 |
Why?
|
| Platelet Membrane Glycoproteins | 3 | 1993 | 13 | 0.210 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 97 | 0.210 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 2065 | 0.200 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 1508 | 0.200 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 1 | 0.200 |
Why?
|
| Protein Biosynthesis | 2 | 2013 | 111 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2022 | 6 | 0.200 |
Why?
|
| RNA-Binding Proteins | 2 | 2014 | 87 | 0.200 |
Why?
|
| Cell Survival | 1 | 2024 | 419 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 166 | 0.190 |
Why?
|
| Endothelium, Vascular | 3 | 2001 | 334 | 0.190 |
Why?
|
| Acidosis | 2 | 2013 | 11 | 0.190 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 13 | 0.190 |
Why?
|
| Sarcosine Dehydrogenase | 2 | 2013 | 4 | 0.190 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 14 | 0.190 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 32 | 0.180 |
Why?
|
| Outpatients | 1 | 2022 | 44 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 44 | 0.180 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2013 | 65 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 23 | 0.180 |
Why?
|
| Signal Transduction | 7 | 2024 | 1469 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 84 | 0.180 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2013 | 87 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 39 | 0.180 |
Why?
|
| Cell Proliferation | 7 | 2024 | 825 | 0.180 |
Why?
|
| Arteriosclerosis | 1 | 2001 | 30 | 0.180 |
Why?
|
| Transcriptome | 2 | 2022 | 231 | 0.170 |
Why?
|
| Mitosis | 2 | 2020 | 115 | 0.170 |
Why?
|
| Genomic Instability | 2 | 2022 | 34 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2022 | 222 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 84 | 0.170 |
Why?
|
| Diabetes Complications | 1 | 2001 | 66 | 0.170 |
Why?
|
| Pyrazines | 1 | 2021 | 25 | 0.170 |
Why?
|
| Benzamides | 1 | 2021 | 39 | 0.170 |
Why?
|
| Animals | 13 | 2024 | 10699 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 142 | 0.170 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2020 | 31 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 42 | 0.160 |
Why?
|
| Chromosomal Instability | 2 | 2018 | 21 | 0.160 |
Why?
|
| Genomics | 1 | 2021 | 125 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 67 | 0.160 |
Why?
|
| Alendronate | 1 | 2019 | 6 | 0.160 |
Why?
|
| Anticarcinogenic Agents | 1 | 2019 | 16 | 0.160 |
Why?
|
| Glucose | 1 | 2001 | 209 | 0.160 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 216 | 0.150 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 300 | 0.150 |
Why?
|
| Metformin | 1 | 2019 | 36 | 0.150 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 58 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 154 | 0.150 |
Why?
|
| Stroke | 1 | 2022 | 261 | 0.150 |
Why?
|
| Brain | 3 | 2020 | 770 | 0.150 |
Why?
|
| Mice | 8 | 2024 | 4808 | 0.140 |
Why?
|
| 5' Untranslated Regions | 2 | 2013 | 9 | 0.140 |
Why?
|
| Cell Lineage | 2 | 2014 | 53 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 634 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 33 | 0.140 |
Why?
|
| Prostate | 2 | 2019 | 52 | 0.140 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 79 | 0.130 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 46 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1995 | 22 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 433 | 0.130 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 7 | 0.130 |
Why?
|
| HIV-1 | 2 | 1995 | 59 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1995 | 60 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 347 | 0.120 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 55 | 0.120 |
Why?
|
| Molecular Sequence Data | 6 | 2001 | 1056 | 0.120 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1995 | 3 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 415 | 0.120 |
Why?
|
| Male | 12 | 2023 | 13931 | 0.120 |
Why?
|
| Hematopoiesis | 1 | 1995 | 25 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 472 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2014 | 427 | 0.110 |
Why?
|
| Sarcosine | 2 | 2013 | 4 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 167 | 0.110 |
Why?
|
| Oocytes | 1 | 2014 | 24 | 0.110 |
Why?
|
| Cellular Reprogramming | 1 | 2014 | 11 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 51 | 0.110 |
Why?
|
| Apoptosis | 4 | 2024 | 780 | 0.110 |
Why?
|
| Spermatozoa | 1 | 2014 | 34 | 0.110 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 61 | 0.110 |
Why?
|
| Macrophages | 1 | 2017 | 305 | 0.110 |
Why?
|
| Integrin alphaV | 1 | 2014 | 3 | 0.110 |
Why?
|
| Integrin beta3 | 1 | 2014 | 7 | 0.110 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2014 | 57 | 0.110 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2014 | 33 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 1994 | 81 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 1351 | 0.100 |
Why?
|
| Stem Cells | 1 | 2014 | 123 | 0.100 |
Why?
|
| Cell Movement | 2 | 2014 | 376 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 22 | 0.100 |
Why?
|
| Female | 7 | 2023 | 15631 | 0.100 |
Why?
|
| Prokaryotic Initiation Factor-2 | 1 | 2013 | 2 | 0.100 |
Why?
|
| Base Sequence | 4 | 2001 | 589 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 190 | 0.100 |
Why?
|
| Androgens | 1 | 2013 | 47 | 0.100 |
Why?
|
| Prognosis | 3 | 2022 | 811 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 1993 | 149 | 0.100 |
Why?
|
| Cell Adhesion | 4 | 2011 | 139 | 0.100 |
Why?
|
| Collagen | 1 | 1993 | 156 | 0.100 |
Why?
|
| Glycoproteins | 2 | 2001 | 124 | 0.100 |
Why?
|
| Carbon | 1 | 2013 | 107 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 44 | 0.090 |
Why?
|
| ras Proteins | 1 | 2012 | 43 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2019 | 668 | 0.090 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 30 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 88 | 0.090 |
Why?
|
| Rituximab | 3 | 2022 | 64 | 0.090 |
Why?
|
| Cyclic AMP | 1 | 2011 | 96 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 95 | 0.090 |
Why?
|
| Benzopyrenes | 1 | 2010 | 1 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 404 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 2024 | 141 | 0.080 |
Why?
|
| Carcinogens | 1 | 2010 | 39 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 1992 | 114 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 166 | 0.080 |
Why?
|
| Organ Specificity | 2 | 2022 | 82 | 0.080 |
Why?
|
| Neoplasms | 2 | 2016 | 874 | 0.080 |
Why?
|
| Rats | 2 | 2024 | 1588 | 0.070 |
Why?
|
| Hemophilia A | 2 | 2002 | 15 | 0.070 |
Why?
|
| Aging | 1 | 2016 | 1017 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2013 | 1022 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 2 | 2018 | 68 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 1658 | 0.070 |
Why?
|
| Thrombospondins | 3 | 1993 | 6 | 0.060 |
Why?
|
| Aged | 4 | 2023 | 5598 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 477 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 483 | 0.060 |
Why?
|
| Middle Aged | 3 | 2023 | 7415 | 0.060 |
Why?
|
| Induction Chemotherapy | 1 | 2025 | 11 | 0.060 |
Why?
|
| Remission Induction | 1 | 2025 | 58 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2020 | 874 | 0.060 |
Why?
|
| Fibrinogen | 1 | 1985 | 50 | 0.060 |
Why?
|
| Adult | 5 | 2023 | 8026 | 0.050 |
Why?
|
| Organoids | 1 | 2024 | 23 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 314 | 0.050 |
Why?
|
| Megakaryocytes | 2 | 1995 | 30 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2001 | 242 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 465 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2001 | 697 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 513 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 676 | 0.050 |
Why?
|
| DNA Primers | 2 | 2001 | 147 | 0.050 |
Why?
|
| Azacitidine | 1 | 2022 | 8 | 0.050 |
Why?
|
| Isoantibodies | 1 | 2002 | 15 | 0.050 |
Why?
|
| SEER Program | 1 | 2023 | 47 | 0.050 |
Why?
|
| Factor VIII | 1 | 2002 | 19 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 34 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 36 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 75 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 32 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 126 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 18 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 42 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2013 | 585 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 65 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 108 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 150 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2014 | 515 | 0.040 |
Why?
|
| Thrombospondin 1 | 1 | 2001 | 8 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 166 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 1996 | 270 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 612 | 0.040 |
Why?
|
| Cell Line | 2 | 1993 | 700 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2001 | 90 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 518 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 336 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2001 | 78 | 0.040 |
Why?
|
| Platelet Aggregation | 2 | 1993 | 44 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 465 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2020 | 18 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2020 | 21 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2001 | 124 | 0.040 |
Why?
|
| Azoxymethane | 1 | 2019 | 20 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 106 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 2019 | 174 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2002 | 481 | 0.040 |
Why?
|
| Lung | 1 | 2022 | 382 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 22 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 190 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 196 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 209 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2018 | 8 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2019 | 90 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 236 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2019 | 163 | 0.040 |
Why?
|
| Proteins | 1 | 2001 | 254 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1280 | 0.040 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2018 | 4 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2018 | 32 | 0.030 |
Why?
|
| Mucins | 1 | 2018 | 25 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 485 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 68 | 0.030 |
Why?
|
| Lidocaine | 1 | 1977 | 27 | 0.030 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2017 | 6 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2017 | 10 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2017 | 12 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 12 | 0.030 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2017 | 16 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 100 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1977 | 57 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 57 | 0.030 |
Why?
|
| Cell Membrane | 2 | 1992 | 268 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 164 | 0.030 |
Why?
|
| Antigens, CD1d | 1 | 2017 | 45 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1996 | 2 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1996 | 2 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 47 | 0.030 |
Why?
|
| Herpesvirus 8, Human | 1 | 1996 | 12 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 2 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 1996 | 19 | 0.030 |
Why?
|
| Herpesviridae Infections | 1 | 1996 | 17 | 0.030 |
Why?
|
| Binding Sites | 2 | 2001 | 355 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 73 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 115 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1996 | 43 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 194 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 285 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 163 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 130 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 194 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 78 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 1995 | 55 | 0.030 |
Why?
|
| Cell Division | 1 | 1995 | 154 | 0.030 |
Why?
|
| Young Adult | 1 | 2023 | 2835 | 0.030 |
Why?
|
| Adolescent | 1 | 2023 | 3194 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 480 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 686 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1994 | 23 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 1994 | 14 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1995 | 112 | 0.030 |
Why?
|
| Cell Shape | 1 | 2014 | 16 | 0.030 |
Why?
|
| Focal Adhesions | 1 | 2014 | 15 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 737 | 0.030 |
Why?
|
| Receptors, Cytoadhesin | 1 | 1993 | 2 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 114 | 0.030 |
Why?
|
| Platelet Adhesiveness | 1 | 1993 | 7 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 1993 | 19 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 129 | 0.030 |
Why?
|
| Microcirculation | 1 | 1994 | 113 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 133 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1993 | 74 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1993 | 132 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 257 | 0.030 |
Why?
|
| Leukopenia | 1 | 1993 | 5 | 0.030 |
Why?
|
| HIV Antigens | 1 | 1993 | 3 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1993 | 11 | 0.030 |
Why?
|
| Methotrexate | 1 | 2013 | 36 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1993 | 25 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 328 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1993 | 89 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 48 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2013 | 39 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 1613 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2013 | 26 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2013 | 44 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 134 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 777 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 80 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 120 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 2635 | 0.020 |
Why?
|
| Oligopeptides | 1 | 1992 | 97 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 69 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2011 | 58 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 270 | 0.020 |
Why?
|
| Transfection | 1 | 1992 | 319 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 44 | 0.020 |
Why?
|
| Glycine | 1 | 2011 | 33 | 0.020 |
Why?
|
| Kinetics | 1 | 1992 | 553 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 247 | 0.020 |
Why?
|
| Melanoma | 1 | 1992 | 140 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 284 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2010 | 3 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 202 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2010 | 31 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 37 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 2426 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 667 | 0.020 |
Why?
|
| DNA Damage | 1 | 2010 | 152 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 381 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 292 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2010 | 677 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1985 | 137 | 0.010 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2002 | 2 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2002 | 3 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 54 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 42 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 70 | 0.010 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2001 | 3 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 133 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 285 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2001 | 148 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 469 | 0.010 |
Why?
|
| Proviruses | 1 | 1996 | 2 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1996 | 6 | 0.010 |
Why?
|
| Negative Staining | 1 | 1996 | 3 | 0.010 |
Why?
|
| Genes, myc | 1 | 1996 | 9 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1996 | 22 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 94 | 0.010 |
Why?
|
| Karyotyping | 1 | 1996 | 25 | 0.010 |
Why?
|
| Genome, Viral | 1 | 1996 | 34 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1996 | 61 | 0.010 |
Why?
|
| Genes, gag | 1 | 1995 | 1 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1995 | 63 | 0.010 |
Why?
|
| Virus Replication | 1 | 1995 | 66 | 0.010 |
Why?
|